SG10201502490YA - Norovirus vaccine formulations - Google Patents

Norovirus vaccine formulations

Info

Publication number
SG10201502490YA
SG10201502490YA SG10201502490YA SG10201502490YA SG10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA
Authority
SG
Singapore
Prior art keywords
vaccine formulations
norovirus vaccine
norovirus
formulations
vaccine
Prior art date
Application number
SG10201502490YA
Inventor
Charles Richardson
Thomas S Vedvick
Thomas R Foubert
William T Tino
Original Assignee
Ligocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201502490Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligocyte Pharmaceuticals Inc filed Critical Ligocyte Pharmaceuticals Inc
Publication of SG10201502490YA publication Critical patent/SG10201502490YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10201502490YA 2006-09-29 2007-09-28 Norovirus vaccine formulations SG10201502490YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84791206P 2006-09-29 2006-09-29
US97339207P 2007-09-18 2007-09-18

Publications (1)

Publication Number Publication Date
SG10201502490YA true SG10201502490YA (en) 2015-05-28

Family

ID=39268804

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201502490YA SG10201502490YA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG2011071123A SG174845A1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG10202012986SA SG10202012986SA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2011071123A SG174845A1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG10202012986SA SG10202012986SA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Country Status (17)

Country Link
US (8) US7955603B2 (en)
EP (4) EP2641613A1 (en)
JP (3) JP5476544B2 (en)
KR (1) KR101515489B1 (en)
AU (1) AU2007303608B2 (en)
CA (1) CA2664157C (en)
CY (1) CY1118492T1 (en)
DK (3) DK2601969T3 (en)
ES (3) ES2577833T3 (en)
HK (1) HK1184057A1 (en)
HU (2) HUE032422T2 (en)
LT (1) LT2601970T (en)
PL (2) PL2601970T3 (en)
PT (1) PT2601970T (en)
SG (3) SG10201502490YA (en)
SI (1) SI2601970T1 (en)
WO (1) WO2008042789A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
CN101918028B (en) 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 Vaccine of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP3382011A1 (en) * 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
SG182636A1 (en) * 2010-01-21 2012-08-30 Ligocyte Pharmaceuticals Inc Targeted heterologous antigen presentation on calicivirus virus-like particles
WO2011129120A1 (en) * 2010-04-15 2011-10-20 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
AU2012244074B2 (en) * 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (en) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
HUE038527T2 (en) * 2012-12-28 2018-10-29 Cellestis Ltd A cell mediated immune response assay
WO2014145245A2 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP2015015931A (en) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ Method for producing culture comprising virus-like particles
JP6479305B2 (en) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ Purification method of virus-like particles
JP2015017065A (en) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ Pharmaceutical composition comprising norovirus virus-like particles
KR20160030961A (en) 2013-07-17 2016-03-21 다우 글로벌 테크놀로지스 엘엘씨 Composition for application to a mucosa comprising a methylcellulose
SG11201602585XA (en) 2013-10-03 2016-05-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
JP6556632B2 (en) * 2013-12-16 2019-08-07 武田薬品工業株式会社 Micro needle
JP7033534B2 (en) * 2015-08-28 2022-03-10 オロジー バイオサーヴィシズ、インク． Norovirus vaccine
KR101914779B1 (en) * 2016-03-18 2018-11-02 (주)인테라 Recombinant Expression Vectors for Producing Norovirus Vaccine
CN107184970A (en) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 Oral norovirus subunit vaccine and LT as the vaccine adjuvant purposes
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
EP3717648A4 (en) 2017-11-30 2021-12-01 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
EP3752185A1 (en) 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (en) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン Norovirus inactivation method for shellfish
EP3821014A4 (en) 2018-07-13 2022-04-20 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
JP2022502482A (en) * 2018-09-17 2022-01-11 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム Compositions and Methods for Treating Bone Damage
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
MX2021011059A (en) 2019-03-12 2021-10-13 Icon Genetics Gmbh Norovirus-like particles with improved stability.
CA3148026A1 (en) * 2019-08-13 2021-02-18 Vyjayanthi Krishnan Therapeutic agent effectiveness and its route of administration
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN117330750A (en) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 Method for screening early virus seed of new coronavirus and method for preparing vaccine

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) * 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
CA2133339A1 (en) 1992-04-08 1993-10-09 Jennifer S. Rota Wild-type measles virus glycoproteins: vaccine and detection method therefor
ATE157882T1 (en) 1993-03-23 1997-09-15 Smithkline Beecham Biolog VACCINE COMPOSITIONS CONTAINING 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
BR9507657A (en) 1994-05-16 1997-09-09 Merck & Co Inc Isolated and purified protein from recombinant papillomavirus capsids virus-like particles immune response in a vertebrate animal pharmaceutical compositions kit for the detection of papillomavirus or antibodies to papillomavirus and sinter system
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
NZ500028A (en) 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
ATE324436T1 (en) 1998-08-14 2006-05-15 Merck & Co Inc METHOD FOR CLEANING HUMAN PARTICLES SIMILAR TO THE PAPILLOMA VIRUS.
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
PT1150712E (en) 1999-02-05 2008-12-22 Merck & Co Inc Human papilloma virus vaccine formulations
EP1186890B1 (en) * 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2849556A1 (en) 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003237528A1 (en) 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
AU2003242742B2 (en) 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (en) 2003-12-19 2006-03-24 Aventis Pasteur IMMUNOSTIMULATING COMPOSITION
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (en) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US20060177468A1 (en) 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
CA2599218C (en) 2005-03-18 2015-08-11 Cytos Biotechnology Ag Cat allergen conjugates and uses thereof
BRPI0611336A2 (en) 2005-06-01 2010-08-31 Dow Global Technologies Inc method of producing a multivalent virus-like particle, multivalent virus-like particle, method of increasing the solubility of a multivalent virus-like particle and vaccine
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
JP2007145775A (en) 2005-11-29 2007-06-14 Falco Life Science:Kk Method for detecting norovirus gi in high sensitivity
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
ES2480491T3 (en) 2006-12-06 2014-07-28 Novartis Ag Vaccines including four influenza virus strains antigen
SG10201701988TA (en) 2007-03-14 2017-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
US8474614B2 (en) * 2007-03-14 2013-07-02 BBY Solutions Protective container for a flat screen monitor
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN101918028B (en) * 2007-09-18 2015-01-07 莱戈赛特医药股份有限公司 Vaccine of conferring a protective immune response to norovirus
EP3382011A1 (en) 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EP2381959A1 (en) 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
SG182636A1 (en) 2010-01-21 2012-08-30 Ligocyte Pharmaceuticals Inc Targeted heterologous antigen presentation on calicivirus virus-like particles
EP2582393A4 (en) 2010-05-26 2014-04-02 Selecta Biosciences Inc Dose selection of adjuvanted synthetic nanocarriers
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (en) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles

Also Published As

Publication number Publication date
AU2007303608A1 (en) 2008-04-10
US9272028B2 (en) 2016-03-01
DK2601970T3 (en) 2017-02-06
US9861691B2 (en) 2018-01-09
EP2601970B1 (en) 2016-10-26
SI2601970T1 (en) 2017-04-26
JP2013234188A (en) 2013-11-21
ES2420136T3 (en) 2013-08-22
CA2664157C (en) 2015-12-01
EP2601969A2 (en) 2013-06-12
KR101515489B1 (en) 2015-04-30
JP5898133B2 (en) 2016-04-06
DK2601969T3 (en) 2016-04-18
HUE032422T2 (en) 2017-09-28
US20130273148A1 (en) 2013-10-17
JP2010505766A (en) 2010-02-25
US10512682B2 (en) 2019-12-24
US20140286994A1 (en) 2014-09-25
EP2601969A3 (en) 2013-08-21
US20080299152A1 (en) 2008-12-04
CA2664157A1 (en) 2008-04-10
PL2601969T3 (en) 2016-10-31
ES2618885T3 (en) 2017-06-22
AU2007303608B2 (en) 2013-05-02
US8431116B2 (en) 2013-04-30
SG174845A1 (en) 2011-10-28
HK1184057A1 (en) 2014-01-17
EP2601970A1 (en) 2013-06-12
LT2601970T (en) 2017-04-25
US7955603B2 (en) 2011-06-07
PT2601970T (en) 2017-02-02
EP2066354A1 (en) 2009-06-10
US20160008455A1 (en) 2016-01-14
EP2066354A4 (en) 2010-10-20
PL2601970T3 (en) 2017-07-31
JP5476544B2 (en) 2014-04-23
US20190125853A1 (en) 2019-05-02
US9308249B2 (en) 2016-04-12
US20130273105A1 (en) 2013-10-17
CY1118492T1 (en) 2017-07-12
HUE028978T2 (en) 2017-02-28
EP2641613A1 (en) 2013-09-25
ES2577833T3 (en) 2016-07-19
US10010599B2 (en) 2018-07-03
JP6134364B2 (en) 2017-05-24
EP2601969B1 (en) 2016-03-30
WO2008042789A1 (en) 2008-04-10
DK2066354T3 (en) 2013-05-27
EP2066354B1 (en) 2013-04-17
KR20090079912A (en) 2009-07-22
US20120093861A1 (en) 2012-04-19
US20120156243A1 (en) 2012-06-21
SG10202012986SA (en) 2021-01-28
JP2016020378A (en) 2016-02-04

Similar Documents

Publication Publication Date Title
HK1184057A1 (en) Norovirus vaccine formulations
GB2435419B (en) Formulations
GB0607088D0 (en) Vaccine
EP2046930A4 (en) Rhamnolipid-based formulations
GB0605780D0 (en) Formulations
ZA200808489B (en) Nicotine-carrier vaccine formulation
GB0618697D0 (en) Formulations
GB0610336D0 (en) Formulations
HK1129836A1 (en) Ipv-dpt vaccine ipv-dpt
ZA200901592B (en) Vaccine
GB0718404D0 (en) Formulations
GB0711440D0 (en) Aqueous formulations
GB0625593D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine
GB0620336D0 (en) Vaccine
GB0607087D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0620337D0 (en) Vaccine
GB0608962D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0620815D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0614476D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0619824D0 (en) Vaccine